Probiodrug has signed an agreement with Rentschler Biotechnologie GmbH for the development of PBD-C06, a pGlu-Abeta-specific monoclonal antibody, as treatment for patients with Alzheimer’s disease.
Biopharmaceutical company, Probiodrug, announced that it has signed an agreement with German-based biopharma manufacturer Rentschler Biotechnologie GmbH for the development of PBD-C06, a pGlu-Abeta-specific monoclonal antibody, as treatment for patients with Alzheimer’s disease.
The contract comprises all stages of production and processing from initial cell-line development through to the manufacturing of material for preclinical and clinical studies. Rentschler is an independent contract manufacturer with experience in producing biopharmaceuticals for more than 40 years.
PBD-C06 is a chimeric, de-immunized monoclonal antibody selected as a candidate with the best safety, efficacy, and pharmacological profile from among several pre-clinical candidates. It targets pGlu-Abeta, aiming to selectively clear the brain of pGlu-Abeta while leaving non-toxic forms of Abeta untouched. In Alzheimer’s disease animal models, PBD-C06 reduced pGlu-Abeta and total Abeta levels and positively affected memory function.
To date Probiodrug has progressed two complementary strategies for tackling pGlu-Abeta, with two medicine candidates in development-PQ912, a small molecule inhibitor of Glutaminyl Cyclase, in phase 2, and PBD-C06, a pGlu-Abeta-specific mAB in preclinical stage.
Source: Probiodrug
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.